Results 131 to 140 of about 551,654 (347)

Engineering Osteoimmune Responses with Functionalized Orthopedic Implants for Post‐Operative Osteosarcoma Treatment

Advanced Science, EarlyView.
Osteosarcoma is the most common primary bone tumor with limited treatment options and a terrible prognosis. This review provides a comprehensive summary of the recent development of osteoimmunomodulatory implants for post‐operative osteosarcoma treatment, of which the potential utility in evoking durable anti‐osteosarcoma immunity and accelerating bone
Yilong Dong, Lingshuang Wang, Hui Zhang, Menghuan Li, Zhong Luo, Yan Hu, Chunyuan Cai   +6 more
wiley   +1 more source

The urgent need to recover MHC class I in cancers for effective immunotherapy

Current Opinion in Immunology, 2016
Highlights • Tumor immune escape compromises the efficacy of cancer immunotherapy.• Loss of MHC class I expression is a frequent event in cancer cells.• Three tumor phenotypes determine cancer fate: escape, rejection and dormancy.• Recovery of MHC class ...
F. Garrido, N. Aptsiauri, E. Doorduijn, A. G. Garcia Lora, T. van Hall   +4 more
semanticscholar   +1 more source

Improved Systemic Immunochemotherapy Employing an Oxaliplatin‐TLR7/8 Agonist Prodrug Strategy

Advanced Science, EarlyView.
A platinum(IV) prodrug is developed to systemically deliver the TLR7/8 agonist gardiquimod. Tumor‐targeting is mediated by an albumin‐binding maleimide, which limits premature complex activation. Ox‐Gardi‐Mal accumulates specifically in the tumor, where it activates the immune system.
Michael Gutmann, Martijn Dijkstra, Philipp Salomon, Jamie Cowles, Anja Federa, Dina Baier, Carola Jaunecker, Iemima Semerean, Venla Karvonen, Christine Pirker, Maria Sibilia, Dietmar Herndler‐Brandstetter, Petra Heffeter, Bernhard K. Keppler, Christian R. Kowol, Walter Berger   +15 more
wiley   +1 more source

MHC matching improves engraftment of iPSC-derived neurons in non-human primates

Nature Communications, 2017
The banking of human leukocyte antigen (HLA)-homozygous-induced pluripotent stem cells (iPSCs) is considered a future clinical strategy for HLA-matched cell transplantation to reduce immunological graft rejection.
A. Morizane, Tetsuhiro Kikuchi, Takuya Hayashi, H. Mizuma, Sayuki Takara, H. Doi, A. Mawatari, M. Glasser, T. Shiina, H. Ishigaki, Y. Itoh, K. Okita, Emi Yamasaki, D. Doi, H. Onoe, K. Ogasawara, S. Yamanaka, J. Takahashi   +17 more
semanticscholar   +1 more source

BGN/MDK Axis in the Melanoma Tumor Microenvironment Strengthens Tumor Malignancy by Modulating Cancer Cells and Cancer‐Associated Fibroblasts Crosstalk

Advanced Science, EarlyView.
This study reveals that m6A regulators cooperatively upregulate BGN in melanoma, promoting malignancy. Within the tumor microenvironment, CAFs show highest BGN expression. The BGN/MDK axis mediates cancer‐stroma crosstalk, driving normal fibroblast (NF) activation and enhancing the pro‐tumor effect of CAFs, highlighting a promising therapeutic target ...
Hao‐ze Shi, Ming‐yang Wu, Jin‐quan Liu, Cuicui Tian, Li Ma, Xue‐mei Zhou, Ze‐Hao Sun, Zhi‐yong Xu, Run‐dong Zhang, Shan‐yuan Ye, Li‐ming Huang, Yan Wang, Jing‐shu Xiong, Wen‐bo Bu, Xian‐feng Cheng, Jian‐fang Sun, Hao Chen   +16 more
wiley   +1 more source

Major Histocompatibility Complex (MHC) Genes and Disease Resistance in Fish

Cells, 2019
Fascinating about classical major histocompatibility complex (MHC) molecules is their polymorphism. The present study is a review and discussion of the fish MHC situation. The basic pattern of MHC variation in fish is similar to mammals, with MHC class I
Takuya Yamaguchi, Johannes M. Dijkstra
doaj   +1 more source

Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement.

JCI Insight, 2018
Immunotherapies targeting the PD-1 pathway produce durable responses in many cancers, but the tumor-intrinsic factors governing response and resistance are largely unknown. MHC-II expression on tumor cells can predict response to anti-PD-1 therapy.
Douglas B. Johnson, Mellissa J. Nixon, Yu Wang, Daniel Y Wang, E. Castellanos, M. V. Estrada, P. Ericsson-Gonzalez, Candace H. Cote, R. Salgado, V. Sanchez, Phillip T. Dean, S. Opalenik, D. Schreeder, D. Rimm, ju young kim, J. Bordeaux, S. Loi, L. Horn, M. Sanders, P. Ferrell, Yaomin Xu, J. Sosman, Randall S. Davis, J. Balko   +23 more
semanticscholar   +1 more source

Identification of a CD4+ T cell-stimulating antigen of pathogenic bacteria by expression cloning. [PDF]

, 1995
Identifying the immunogenic proteins that elicit pathogen-specific T cell responses is key to rational vaccine design. While several approaches have succeeded in identifying major histocompatibility complex (MHC) class I bound peptides that stimulate CD8+
Campbell, D, Sanderson, S, SHASTRI, Nilabh   +2 more
core   +1 more source

Decoding Triphenotypic Neutrophils in Cervical Cancer Evolution and Targeting SPP1+/GBP1+/ELOVL5+ Tumor‐Associated Neutrophils to Sensitize Immunotherapy

Advanced Science, EarlyView.
The functional schematic diagram of tumor associated neutrophils. Abstract Enhancing cervical cancer (CC) immunotherapy requires deciphering the heterogeneous tumor immune microenvironment (TIME), particularly neutrophil phenotypic dynamics. Here, 1) we collected 543 CC cases to find that patients with elevated neutrophil levels have a higher incidence
Xingyu Chang, Xinyu Qu, Tingting Ren, Tong Wu, Weiyong Gu, Jingxin Ding, Keqin Hua, Junjun Qiu   +7 more
wiley   +1 more source

Regulation of MHC Class II-Peptide Complex Expression by Ubiquitination

Frontiers in Immunology, 2013
MHC class II (MHC-II) molecules are present on antigen presenting cells (APCs) and these molecules function by binding antigenic peptides and presenting these peptides to antigen-specific CD4+ T cells.
Kyung Jin eCho, Paul A. Roche
doaj   +1 more source